|
| 產(chǎn)地 | 進(jìn)口、國(guó)產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號(hào) | CS11419 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號(hào) | |
| 抗體名 | Anti-SRC |
| 克隆性 | |
| 靶點(diǎn) | 詳見(jiàn)說(shuō)明書(shū) |
| 適應(yīng)物種 | 詳見(jiàn)說(shuō)明書(shū) |
| 形態(tài) | 詳見(jiàn)說(shuō)明書(shū) |
| 宿主 | 詳見(jiàn)說(shuō)明書(shū) |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | 詳見(jiàn)說(shuō)明書(shū) |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from mouse SRC N-terminus |
中文名稱 src原癌基因抗體品牌
英文名稱 Anti-SRC
別 名 ASV; Avian sarcoma virus; c SRC; CDNA FLJ14219 fis clone NT2RP3003800 highly similar to Rattus norvegicus tyrosine protein kinase pp60 c src mRNA; cSrc; EC 2.7.10.2; Neuronal CSRC tyrosine specific protein kinase; Neuronal SRC; Oncogene SRC; OTTHUMP00000030931; OTTHUMP00000174476; OTTHUMP00000174477; p60 Src; p60-Src; p60Src; pp60c src; pp60c-src; pp60csrc; Proto oncogene tyrosine protein kinase Src; Proto-oncogene c-Src; Proto-oncogene tyrosine-protein kinase Src; Protooncogene SRC; protooncogene SRC Rous sarcoma; Src; SRC Oncogene; SRC_MOUSE; SRC1; Tyrosine kinase pp60c src; Tyrosine protein kinase SRC 1; Tyrosine protein kinase SRC1; v src avian sarcoma (Schmidt Ruppin A2) viral oncogene homolog; V src sarcoma (Schmidt Ruppin A 2) viral oncogene homolog (avian); v src sarcoma (Schmidt Ruppin A 2) viral oncogene homolog avian; vsrc avian sarcoma (Schmidt Ruppin A2) viral oncogene homolog.
產(chǎn)品屬性：
src原癌基因抗體品牌 濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來(lái)源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog, Cow
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 免疫學(xué) 染色質(zhì)和核信號(hào) 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 激酶和磷酸酶 表觀遺傳學(xué)
蛋白分子量 predicted molecular weight: 61kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from mouse SRC N-terminus
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
src原癌基因抗體品牌 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 c-Src tyrosine kinase plays a critical role in signal transduction downstream of growth factor receptors, integrins and G protein-coupled receptors. We used stable isotope labeling with amino acids in cell culture (SILAC) approach to identify additional substrates of c-Src tyrosine kinase in human embryonic kidney 293T cells. We have identified 10 known substrates and interactors of c-Src and Src family kinases along with 26 novel substrates. We have experimentally validated 4 of the novel proteins (NICE-4, RNA binding motif 10, FUSE-binding protein 1 and TRK-fused gene) as direct substrates of c-Src using in vitro kinase assays and cotransfection experiments. Significantly, using a c-Src specific inhibitor, we were also able to implicate 3 novel substrates (RNA binding motif 10, EWS1 and Bcl-2 associated transcription factor) in PDGF signaling. Finally, to identify the exact tyrosine residues that are phosphorylated by c-Src on the novel c-Src substrates, we designed custom peptide microarrays containing all possible tyrosine-containing peptides (312 unique peptides) and their mutant counterparts containing a Tyr --> Phe substitution from 14 of the identified substrates. Using this platform, we identified 34 peptides that are phosphorylated by c-Src. We have demonstrated that SILAC-based quantitative proteomics approach is suitable for identification of substrates of nonreceptor tyrosine kinases and can be coupled with peptide microarrays for high-throughput identification of substrate phosphopeptides.
Function : Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1 and to localize to actin filaments. Cytoskeletal reorganization is also controlled through the phosphorylation of cortactin (CTTN). When cells adhere via focal adhesions to the extracellular matrix, signals are transmitted by integrins into the cell resulting in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN). In addition to phosphorylating focal adhesion proteins, SRC is also active at the sites of cell-cell contact adherens junctions and phosphorylates substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1), and plakoglobin (JUP). Another type of cell-cell junction, the gap junction, is also a target for SRC, which phosphorylates connexin-43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing and phosphorylates RNA-binding proteins such as KHDRBS1. Also plays a role in PDGF-mediated tyrosine phosphorylation of both STAT1 and STAT3, leading to increased DNA binding activity of these transcription factors. Involved in the RAS pathway through phosphorylation of RASA1 and RASGRF1. Plays a role in EGF-mediated calcium-activated chloride channel activation. Required for epidermal growth factor receptor (EGFR) internalization through phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization through phosphorylation and activation of ADRBK1, leading to beta-arrestin phosphorylation and internalization. Has a critical role in the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase cascade by epidermal growth factor. Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus. Plays an important role in osteoclastic bone resorption in conjunction with PTK2B/PYK2. Both the formation of a SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for this function. Recruited to activated integrins by PTK2B/PYK2, thereby phosphorylating CBL, which in turn induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. Promotes energy production in osteoclasts by activating mitochondrial cytochrome C oxidase. Phosphorylates DDR2 on tyrosine residues, thereby promoting its subsequent autophosphorylation. Phosphorylates RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731'. Enhances DDX58/RIG-I-elicited antiviral signaling. Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376' (By similarity). Phosphorylates BCAR1 at 'Tyr-132' (By similarity).
Subunit : Interacts with CDCP1, PELP1, TGFB1I1 and TOM1L2 (By similarity). Interacts with DDEF1/ASAP1 via its SH3 domain. Interacts with CCPG1. Interacts with the cytoplasmic domain of MUC1, phosphorylates it and increases binding of MUC1 with beta-catenin. Interacts with RALGPS1 via its SH3 domain. Interacts with CAV2 (tyrosine phosphorylated form). Interacts (via the SH3 domain and the protein kinase domain) with ARRB1; the interaction is independent of the phosphorylation state of SRC C-terminus. Interacts with FCAMR and PXN. Interacts with ARRB2. Interacts with ARRB1. Interacts with SRCIN1 (By similarity). Interacts with SRCIN1. Interacts with NDFIP2 and more weakly with NDFIP1. Interacts with PIK3CA and/or PIK3C2B, PTK2/FAK1, ESR1 (dimethylated on arginine) and FAK. Interacts (via SH2 and SH3 domain) with TNK2. Interacts (via protein kinase domain) with the tyrosine phosphorylated form of RUNX3 (via runt domain). Interacts with TRAF3 (via RING-type zinc finger domain). Interacts with DDX58, MAVS and TBK1. Interacts (via SH2 domain) with GNB2L1/RACK1; the interaction is enhanced by tyrosine phosphorylation of GNB2L1 and inhibits SRC activity (By similarity). Interacts (via SH2 domain) with the 'Tyr-402' phosphorylated form of PTK2B/PYK2. Interacts (via SH2 domain) with FLT3 (tyrosine phosphorylated). Identified in a complex containing FGFR4, NCAM1, CDH2, PLCG1, FRS2, SRC, SHC1, GAP43 and CTTN. Interacts with EPHB1; activates the MAPK/ERK cascade to regulate cell migration. Interacts with ERBB2 and STAT1. Interacts with PDGFRA (tyrosine phosphorylated). Interacts with CSF1R. Interacts (via SH2 domain) with the 'Tyr-9' phosphorylated form of PDPK1. Interacts with DDR2. Interacts with AMOTL2; this interaction regulates the translocation of phosphorylated SRC to peripheral cell-matrix adhesion sites. Interacts with DDR1 and DAB2. [INTERACTION] Q63767:Bcar1 (xeno); NbExp=2; IntAct=EBI-298680, EBI-1176801; P07141:Csf1; NbExp=2; IntAct=EBI-298680, EBI-777188; Q8T4F7:ena (xeno); NbExp=2; IntAct=EBI-298680, EBI-466810; P54763:Ephb2; NbExp=3; IntAct=EBI-298680, EBI-537711; P05106:ITGB3 (xeno); NbExp=5; IntAct=EBI-298680, EBI-702847; P49023:PXN (xeno); NbExp=2; IntAct=EBI-298680, EBI-702209; Q01973:ROR1 (xeno); NbExp=3; IntAct=EBI-298680, EBI-6082337; P70315:Was; NbExp=2; IntAct=EBI-298680, EBI-644195.
Subcellular Location : Cell membrane. Mitochondrion inner membrane. Nucleus. Cytoplasm, cytoskeleton. Note=Localizes to focal adhesion sites after integrin engagement. Localization to focal adhesion sites requires myristoylation and the SH3 domain.
Tissue Specificity : Expressed ubiquitously. Platelets, neurons and osteoclasts express 5-fold to 200-fold higher levels than most other tissues.
Post-translational modifications : Myristoylated at Gly-2, and this is essential for targeting to membranes (By similarity).
Dephosphorylated at Tyr-535 by PTPRJ (By similarity). Phosphorylated on Tyr-535 by c-Src kinase (CSK). The phosphorylated form is termed pp60c-src. Dephosphorylated by PTPRJ at Tyr-424. Normally maintained in an inactive conformation with the SH2 domain engaged with Tyr-535, the SH3 domain engaged with the SH2-kinase linker, and Tyr-424 dephosphorylated. Dephosphorylation of Tyr-535 as a result of protein tyrosine phosphatase (PTP) action disrupts the intramolecular interaction between the SH2 domain and Tyr-535, Tyr-424 can then become autophosphorylated, resulting in SRC activation. Phosphorylation of Tyr-535 by CSK allows this interaction to reform, resulting in SRC inactivation. CDK5-mediated phosphorylation at Ser-74 targets SRC to ubiquitin-dependent degradation and thus leads to cytoskeletal reorganization. Phosphorylated by PTK2/FAK1; this enhances kinase activity. Phosphorylated by PTK2B/PYK2; this enhances kinase activity (By similarity).
S-nitrosylation is important for activation of its kinase activity (By similarity).
Ubiquitinated in response to CDK5-mediated phosphorylation.
Similarity : Belongs to the protein kinase superfamily. Tyr protein kinase family. SRC subfamily.
Contains 1 protein kinase domain.
Contains 1 SH2 domain.
Contains 1 SH3 domain.
Database links : UniProtKB/Swiss-Prot: P05480.4
src原癌基因具有酪氨酸激酶活性，參與調(diào)節(jié)正常細(xì)胞的生長(zhǎng)與分化，在控制細(xì)胞增殖的信息轉(zhuǎn)導(dǎo)途徑中起作用；src原癌基因同樣有活化癌基因的作用，能夠誘導(dǎo)細(xì)胞的異常增殖和導(dǎo)致發(fā)生。
實(shí)驗(yàn)流程：
全、新、優(yōu)、品、好四大特點(diǎn)：
src原癌基因抗體品牌 全：公司提供上萬(wàn)種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標(biāo)準(zhǔn)品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細(xì)胞等，基本上各種科研所需產(chǎn)品在我司都能找到。
新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。
優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。
好：我公司具有優(yōu)質(zhì)的技術(shù)團(tuán)隊(duì)，產(chǎn)品一旦售出，實(shí)驗(yàn)過(guò)程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時(shí)沒(méi)有任何的后顧之憂。
技術(shù)外包服務(wù):
★src原癌基因抗體品牌 分子生物學(xué)：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學(xué)：基因合成、引物合成、基因測(cè)序、載體構(gòu)建等
★蛋白工程：原核、哺乳動(dòng)物蛋白表達(dá)系統(tǒng)等
★病毒包裝：腺病毒、慢病毒等
★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等
★細(xì)胞工程：細(xì)胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復(fù)、克隆形成)、細(xì)胞培養(yǎng)、細(xì)胞膜制備、穩(wěn)定細(xì)胞株構(gòu)建、細(xì)胞RNAi技術(shù)等等。
正在熱銷的相關(guān)產(chǎn)品：
Anti-VEGF-B/FITC 熒光素標(biāo)記內(nèi)皮生長(zhǎng)因子B抗體IgGMulti-class antibodies規(guī)格： 0.2ml
CD82/KAI1 peptide 轉(zhuǎn)移抑制蛋白1抗原Multi-class antibodies規(guī)格： 0.5mg
CD38抗體(人) Anti-CD38 0.1ml
Substance P 英文名稱： P物質(zhì)抗體 0.1ml
EIF5 英文名稱： 真核翻譯起始因子5抗體 0.2ml
Rhesus antibody Rh phospho-Gria2 (Ser880) 磷酸化谷氨酸受體2抗體 規(guī)格 0.1ml
CD82/KAI1 peptide 轉(zhuǎn)移抑制蛋白1抗原Multi-class antibodies規(guī)格： 0.5mg
Anti-TGM3/FITC 熒光素標(biāo)記轉(zhuǎn)谷氨酰酶3抗體IgGMulti-class antibodies規(guī)格： 0.2ml
phospho-ATF2(pSer490/pSer498) 磷酸化活化復(fù)制因子2抗原Multi-class antibodies規(guī)格： 0.5mg
肺表面活性蛋白B抗體 Anti-SP-B 0.1ml
SCN8A 英文名稱： 通道蛋白8α抗體 0.1ml
Anei-ENPP2 英文名稱： 自分泌運(yùn)動(dòng)因子抗體 0.1ml
Rhesus antibody Rh phospho-MAP4K4(Ser629) 磷酸化原活化蛋白激酶MAP4K4抗體 規(guī)格 0.1ml
phospho-ATF2(pSer490/pSer498) 磷酸化活化復(fù)制因子2抗原Multi-class antibodies規(guī)格： 0.5mg
PLAU/uPA (Plasminogen activator,urokinase) 尿激酶型纖溶酶原激活因子(多肽)Multi-class antibodies規(guī)格： 0.5mg
Anti-AVPR2 精氨酸加壓素受體2抗體Multi-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh phospho-AKT2 (Ser474) 磷酸化蛋白激酶B2抗體 規(guī)格 0.1ml
Myeloperoxidase 濃縮液 0.1ml 進(jìn)口分裝
UGDH 英文名稱： 尿苷二磷酸葡萄糖脫氫酶抗體 0.2ml
DNAJC3 英文名稱： 干擾素誘導(dǎo)蛋白p58ipk抗體 0.1ml
Anti-AVPR2 精氨酸加壓素受體2抗體Multi-class antibodies規(guī)格： 0.2ml
IL27 Protein Human 重組人 IL27 / Ierleukin-27 蛋白 (His 標(biāo)簽)
小鼠腎上皮細(xì)胞完全培養(yǎng)基 100mL
CPA2 Others Mouse 小鼠 Carboxypeptidase A2 / CPA2 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
97H人細(xì)胞 97H human hepatocarcinoma cells DMEM+10%FBS
CM-M023小鼠淋巴管內(nèi)皮細(xì)胞完全培養(yǎng)基100mL
TT(人甲狀腺導(dǎo)管癌細(xì)胞) 5×106cells/瓶×2 NCI-H838 [H838](人細(xì)胞)
CM-M023小鼠淋巴管內(nèi)皮細(xì)胞完全培養(yǎng)基100mL
CPA2 Others Mouse 小鼠 Carboxypeptidase A2 / CPA2 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
小鼠腎上皮細(xì)胞完全培養(yǎng)基 100mL
97H人細(xì)胞 97H human hepatocarcinoma cells DMEM+10%FBS
IL27 Protein Human 重組人 IL27 / Ierleukin-27 蛋白 (His 標(biāo)簽)
TT(人甲狀腺導(dǎo)管癌細(xì)胞) 5×106cells/瓶×2 NCI-H838 [H838](人細(xì)胞)
src原癌基因抗體品牌 IL27 Protein Human 重組人 IL27 / Ierleukin-27 蛋白 (His 標(biāo)簽)
小鼠腎上皮細(xì)胞完全培養(yǎng)基 100mL
CPA2 Others Mouse 小鼠 Carboxypeptidase A2 / CPA2 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
97H人細(xì)胞 97H human hepatocarcinoma cells DMEM+10%FBS
CM-M023小鼠淋巴管內(nèi)皮細(xì)胞完全培養(yǎng)基100mL
TT(人甲狀腺導(dǎo)管癌細(xì)胞) 5×106cells/瓶×2 NCI-H838 [H838](人細(xì)胞)
|
|
|
|
|
